Gatifloxacin ophthalmic solution 0.3% in the treatment of bacterial keratitis

References

• Pollock GA, McKelvie PA, McCarty DJ, White, JF, Mallari, PL, Taylor, HR. In vivo effects of fluoroquinolones on rabbit corneas. Clin. Exp. Ophthalmol.33, 517–521 (2003).
   Google Scholar
• Kowalski RP, Kowalski BR, Romanowski EG, Mah FS, Thompson PP, Gordon YJ. The in vitro impact of moxifloxacin and gatifloxacin concentration (0.5% vs 0.3%) and the addition of benzalkonium chloride on antibacterial efficacy. Am. J. Ophthalmol.142, 730–735 (2006).
   PubMedGoogle Scholar
• Keam SJ, Croom KF, Keating GM. Gatifloxacin: a review of its use in the treatment of bacterial infections in the US. Drugs65, 695–724 (2005).
   PubMedGoogle Scholar
• Kaliamurthy J, Nelson Jesudasan CA, Geraldine P, Parmar P, Kalavathy CM, Thomas PA. Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics. Ophthalmic. Res. 37, 117–122 (2005).
   PubMed Web of Science ®Google Scholar
• McDermot M, Wheater M. In vitro comparison of the effects of clinically available ophthalmic solution of gatifloxacin 0.3% and moxifloxacin 0.5% on human corneal and conjunctival epithelial cell adhesion and migration and on collagen type IV protein expression. Cornea25, S255–S30 (2006).
   Google Scholar
• Walter K, Tyler ME. Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases. Cornea25, S855–S857 (2006).
   PubMed Web of Science ®Google Scholar
• Forster RK. Conrad Behrens Lecture. The management of infectious keratitis as we approach the 21st Century. CLAO J.24, 175–180 (1998).
   PubMedGoogle Scholar
• Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology106, 1313–1318 (1999).
   PubMed Web of Science ®Google Scholar
• Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology106, 1319–1323 (1999).
   PubMed Web of Science ®Google Scholar
• Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology105, 1853–1854 (1999).
   Google Scholar
• Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am. J. Ophthalmol.121, 712–715 (1996).
   PubMed Web of Science ®Google Scholar
• Mather R, Karenchak L, Romanowski E, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am. J. Ophthalmol.133, 463–466 (2002).
   PubMed Web of Science ®Google Scholar
• Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr. Opin. Ophthalmol.15, 316–320 (2004).
   PubMedGoogle Scholar
• Fung-Tomc J, Gradelski E, Huczco E, Minassian B, Bonner DP. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants. Int. J. Antimicrob. Agents18, 77–80. (2001).
   PubMed Web of Science ®Google Scholar
• Perry CM, Ormrod D, Hurst M, Onrust SV. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs62, 169–207 (2002).
   PubMed Web of Science ®Google Scholar
• Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Micro. Molec. Bio. Rev.61, 377–392 (1997).
   PubMed Web of Science ®Google Scholar
• McLeod SD. Integrating Iquix, Vigamox, and Zymar in the management of ocular infectious disease. Ophthalmol. Clin.46(4), 41–45 (2006).
   PubMedGoogle Scholar
• Allergan, Inc. NDA 21-493 (2003).
   Google Scholar
• Parmar P, Salman A, Kalavathy CM et al. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am. J. Ophthalmol.141, 282–286 (2006).
   PubMed Web of Science ®Google Scholar
• Morrissey I, Burnett R, Viljoen L, Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002. J. Infect.49, 109–114 (2004).
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Borsos S, Hesje CK. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus. J. Chemother.19,146–151 (2007).
   PubMed Web of Science ®Google Scholar
• Kowalski RP, Dhaliwal DK, Karenchak LM et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am. J. Ophthalmol.136, 500–505 (2003).
   PubMed Web of Science ®Google Scholar
• Callegan MC, Ramirez R, Kane ST, Cochran DC, Jensen H. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv. Ther.20, 246–252 (2003).
   PubMed Web of Science ®Google Scholar
• Duggirala A, Joseph J, Sharma S, Nutheti R, Garg P, Das T. Activity of newer fluoroquinolones against Gram-positive and Gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J. Ophthalmol.55, 15–19 (2007).
   PubMedGoogle Scholar
• Solomon R, Donnenfeld ED, Perry HD et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology112, 446–449 (2005).
   Google Scholar
• McCulley JP, Caudle D, Aranowicz JD, Shine WE. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology113, 955–959 (2006).
   PubMed Web of Science ®Google Scholar
• Kim DH, Stark WJ, O’Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology112, 1992–1996 (2006).
   Google Scholar
• Ong-Tone L. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery. J. Cataract. Refract. Surg.33, 59–62 (2007).
   PubMed Web of Science ®Google Scholar
• Costello P, Bakri S, Beer PM et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina26, 191–195 (2006).
   PubMed Web of Science ®Google Scholar
• Price MO, Price FW, Maclellan D. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. J. Cataract. Refract. Surg.31, 2137–2141 (2005).
   PubMed Web of Science ®Google Scholar
• Moshirfar M, Marx DP, Kumar R. The effect of the fourth-generation fluoroquinolones on corneal reepithelialization after penetrating keratoplasty. Cornea24, 833–836 (2005).
   PubMed Web of Science ®Google Scholar
• Kovoor TA, Kim AS, McCulley JP et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens30, 90–94 (2004).
   PubMedGoogle Scholar
• Ly LT, Cavanagh HD, Petroll WM. Confocal assessment of the effects of fourth-generation fluoroquinolones on the cornea. Eye Contact Lens32, 161–165 (2006).
   PubMedGoogle Scholar
• Burka JM, Bower KS, Vonroekel RC, Stutzman RD, Kuzmovych CP, Howard RS. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy. Am. J. Ophthalmol.140, 83–87. (2005).
   PubMed Web of Science ®Google Scholar
• Herrygers LA, Noecker RJ, Lane LC, Levine JM. Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols. Cornea24, 66–71 (2005).
   PubMed Web of Science ®Google Scholar
• Barequet IS, Habot-Wilner Z, Lavinsky F, Ziv H, Belkin M, Rosner M. Effect of fourth-generation fluoroquinolones on the healing rate of corneal erosions in an animal model. Cornea26, 606–609 (2007).
   PubMedGoogle Scholar
• Price MO, Quillin C, Price FW. Effect of gatifloxacin ophthalmic solution 0.3% on human corneal endothelial cell density and aqueous humor gatifloxacin concentration. Curr. Eye Res.30, 563–567 (2005).
   PubMed Web of Science ®Google Scholar
• Awwad ST, Haddad W, Wang MX, Parmar D, Conger D, Cavanagh HD. Corneal intrastromal gatifloxacin crystal deposits after penetrating keratoplasty. Eye Contact Lens30, 169–172 (2004).
   PubMedGoogle Scholar
• Moshirfar M, Feiz V, Vitale AT, Wegelin JA, Basavanthappa S, Wolsey DH. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series. Ophthalmology114, 686–691 (2007).
   PubMed Web of Science ®Google Scholar
• Deramo VA, Lai JC, Fastenberg DM, Udell IR. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am. J. Ophthalmol.142, 721–725 (2006).
   PubMed Web of Science ®Google Scholar
• Miller D, Flynn PM, Scott IU et al. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch. Ophthalmol.124, 479–483 (2006).
   PubMed Web of Science ®Google Scholar
• Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv. Ophthalmol.49(Suppl. 2), S79–S83 (2004).
   PubMed Web of Science ®Google Scholar
• Butler MM, LaMarr WA, Foster KA et al. Antibacterial activity and mechanism of action of a novel aniliuracil-fluoroquinolone hybrid compound. Antimicrob. Agents Chemother.51, 119–127 (2007).
   PubMed Web of Science ®Google Scholar